Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 14, 2016
The pharmacogenomics of drug resistance to protein kinase inhibitorsNancy K Gillis, Howard L McLeodNeuropsychiatric Disease and Treatment|September 21, 2011
An in vitro evaluation of guanfacine as a substrate for P-glycoproteinNancy K Gillis, Hao-Jie Zhu, John S MarkowitzPharmacotherapy|February 25, 2017
Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug UseCory M Vela, Todd C Knepper, Nancy K Gillis, et al.Oncotarget|February 1, 2018
Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitorsNancy K Gillis, Daniel M Rotroff, Tania E Mesa, et al.The Oncologist|February 10, 2017
Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee ExperienceTodd C Knepper, Gillian C Bell, J Kevin Hicks, et al.The Lancet. Oncology|December 9, 2016
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control studyNancy K Gillis, Markus Ball, Qing Zhang, et al.Plos One|October 12, 2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) studyCaitrin W McDonough, Nancy K Gillis, Abdullah Alsultan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2018
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing AssaysCatherine C Coombs, Nancy K Gillis, Xianming Tan, et al.Pageof 1